https://www.selleckchem.com/pr....oducts/afuresertib-g
Background and Purpose Pervious studies have demonstrated that the loss of EGFR T790M after Osimertinib treatment may be the cause of Osimertinib resistance. Here, we conducted a meta-analysis to evaluate the association between the persistence of EGFR T790M and the clinical benefits of Osimertinib in non-small cell lung cancer (NSCLC) patients with baseline EGFR T790M mutation. Experimental design and Methods PUBMED, EMBASE, and Cochrane databases were searched for eligible studies that provided the survival outcomes inc
Мне нравится
Комментарий
Перепост
